#Synecta
LightNews LightNews
newsen.bsky.social
BlueWhale Bio Reports Significant Advances in Immune Cell Therapy Operations and Platform#USA#Philadelphia#BlueWhale_Bio#Synecta#T1_Enhanced
BlueWhale Bio Reports Significant Advances in Immune Cell Therapy Operations and Platform
BlueWhale Bio announces remarkable enhancements in its cell therapy platform and manufacturing operations, underscoring ongoing progress in CAR-T therapies.
third-news.com
October 5, 2026 at 12:23 PM
newsen.bsky.social
BlueWhale Bio Initiates Groundbreaking Clinical Trial for Cancer Treatment Using Innovative Nanoparticles#USA#Philadelphia#BlueWhale_Bio#Synecta_T1#CDNPs
BlueWhale Bio Initiates Groundbreaking Clinical Trial for Cancer Treatment Using Innovative Nanoparticles
BlueWhale Bio has announced the successful dosing of the first patient in a clinical trial utilizing Synecta™ T1 cell-derived nanoparticles, focusing on enhanced immune therapies for cancer treatment.
third-news.com
September 3, 2025 at 12:30 PM
l2plabs.bsky.social
BlueWhale Bio Receives FDA Advanced Manufacturing Technology (AMT) Designation for Synecta™ Cell-Derived Nanoparticle Platform
PHILADELPHIA, Nov. 18, 2025 /PRNewswire/ -- BlueWhale Bio, Inc., a company dedicated to transforming immune cell therapy manufacturing, today announced that its Synecta™ cell-derived nanoparticle (CDNP) platform for immune cell activation has been granted Advanced Manufacturing Technology...
dlvr.it
November 18, 2025 at 1:06 PM
l2plabs.bsky.social
BlueWhale Bio Announces First Patient Dosed in Clinical Trial Using Synecta™ T1 Cell-Derived Nanoparticles (CDNPs)
PHILADELPHIA, Sept. 3, 2025 /PRNewswire/ -- BlueWhale Bio, a company dedicated to transforming immune cell therapy manufacturing, today announced that the first patient has been dosed in a clinical trial at the University of Pennsylvania (NCT04684563). The trial uses BlueWhale Bio's...
dlvr.it
September 3, 2025 at 12:23 PM